- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02012647
Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease
Evaluating Cortical Physiology Following Unilateral and Bilateral Subthalamic Deep Brain Stimulation in Parkinson's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screening evaluation: The Investigators will ask questions to see if the participant qualifies to be in the study. The screening visit will occur up to 4 months before the first study visit, and can be scheduled to occur on the same day as the first study visit. This evaluation will include a review of medical history and clinical findings related to Parkinson's Disease (if applicable). There may be a neurological exam (physical exam). Women of child bearing potential will take a urine pregnancy test. If applicable, the medications currently used to treat Parkinson's Disease symptoms will be reviewed and subjects will be asked to discontinue them for some hours on the days of the study visits. The investigators do not expect concerns or unwanted consequences arising either from discontinuing the Parkinson's Disease medications or turning off the DBS stimulator for the duration of time proposed in the study.
Participants will be studied under 4 conditions, over a span of as few as two days to as long as two months. The four Conditions are : 1) The DBS stimulator will be turned OFF for both sides. 2) The DBS stimulator will be turned ON for the right side. 3) The DBS stimulator will be turned ON for the left side. 4) The DBS stimulator will be turned ON for both sides. The order of these conditions will be picked randomly.
Participants will be asked not to take PD medications for approximately 12 hours prior to the scheduled visit time, and until after the physiological testing.
Healthy controls will be studied on only one occasion, as they do not have DBS.
Tests performed for each study condition:
- Parkinson's Participants Only: A neurological examination will be performed by administering several clinical scaled. These clinical scales include the Unified Parkinson's Disease Rating Scale (UPDRS), the self-report Parkinson's Disease Quality of life scale (PDQ-39), MMSE instrument for cognitive (or memory) testing, and Beck Depression Inventory (BDI II) for evaluation of mood and depressive symptoms. The PDQ-39, MMSE, and BDI will each only be administered once and therefore will not be repeated at every study visit.
- The investigators will determine individual motor evoked potential (MEP) thresholds before beginning the study treatment. MEP will be recorded from a muscle located between the right thumb and index finger, and then from the left thumb and index finger. MEP threshold refers to the amount of stimulation to the brain that is required to activate muscle cells enough to appear on an electromyography (EMG), which records electrical potential in muscle through electrodes placed on the skin.
- The investigators will use TMS to test motor cortex functions. For these tests, participants will sit in a chair that looks like the one at the dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp.
- The investigators will collect data about the muscles of both the upper and lower limbs with a wireless EMG procedure. To do this, small wireless sensors will be placed on the skin over both arm and leg muscles. Participants will be asked to sit in a chair and perform movements with the upper and lower limbs while the EMG records measurements about movement activity. This procedure will be conducted separately for the upper and lower limbs.
- Participants who have provided consent will be videotaped during the visits.
- Side effects and adverse events pertaining to this study will be recorded at each visit.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32607
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-80 years
- Diagnosis of Parkinson's Disease with bilateral subthalamic nucleus (STN) DBS
Exclusion Criteria:
- Cardiac pacemakers
- Need for diathermy
- Repeat MRI scanning
- Anticoagulant therapy
- Previous neuro surgical procedure or ablative therapy
- Frank dementia according to cognitive screening
- History of seizures
- Pregnancy
- Presence of a terminal illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: People with Parkinsons Disease
Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain.
These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
|
Participants sit in a chair that looks like one in a dentist's office.
A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand.
A second magnetic coil will be placed on the scalp of the opposite side.
Recordings from both hands will be made using the magnetic coils placed on scalp.
Results will be compared for participants with and without Parkinson's Disease.
Participants will be asked to move their upper and lower limbs while seated in a chair.
Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure.
Upper and lower limb testing will be performed separately.
|
PLACEBO_COMPARATOR: Healthy Controls
These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls.
These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
|
Participants sit in a chair that looks like one in a dentist's office.
A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand.
A second magnetic coil will be placed on the scalp of the opposite side.
Recordings from both hands will be made using the magnetic coils placed on scalp.
Results will be compared for participants with and without Parkinson's Disease.
Participants will be asked to move their upper and lower limbs while seated in a chair.
Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure.
Upper and lower limb testing will be performed separately.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor Cortex Excitability
Time Frame: As few as 1 days and up to 4 months
|
We will measure Motor Cortex Excitability by examining circuitries of inhibition found in the motor cortex which have a reduced function in Parkinson's Disease.
|
As few as 1 days and up to 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relation between Unified Parkinson's Disease Rating Scale outcomes and physiological measures
Time Frame: As few as 2 days and up to 4 months
|
The Unified Parkinson's Disease Rating Scale (UPDRS) is used by neurologists to rate the motor impairment of people with Parkinson's Disease. The rater obtains the score by observation and questioning the participant. Higher scores represent greater impairment and scores range from 0-108. The data collected from the UPDRS will be compared to physiological data collected with EMG during limb movement tasks. These tasks are used to gather data about skeletal muscle movements. The EMG data will be evaluated individually with an EMG paradigm considering velocity of movement and both antagonist and agonist burst patterns. |
As few as 2 days and up to 4 months
|
Transcallosal Pathway Excitability
Time Frame: As few as 2 days and up to 4 months
|
The investigators will examine the effects of unilateral and bilateral stimulation on the excitability of transcallosal pathway, using specific parameters of Transcranial Magnetic Stimulation (TMS).
|
As few as 2 days and up to 4 months
|
Physiological Measures
Time Frame: One day
|
Physiological data will be collected from healthy controls with EMG during limb movement tasks.
These tasks are used to gather data about skeletal muscle movements.
The EMG data will be evaluated individually with an EMG paradigm considering velocity of movement and both antagonist and agonist burst patterns.
|
One day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aparna Wagle Shukla, MD, University of Florida Center for Movement Disorders and Neurorestoration
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-2013
- 40115065-2 (OTHER: UF Research and Compliance Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Transcranial Magnetic Stimulation (TMS)
-
Emory UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Centre Hospitalier St AnneNot yet recruitingTreatment Resistant Schizophrenia
-
University of California, San DiegoNational Institutes of Health (NIH)RecruitingMajor Depressive DisorderUnited States, Australia
-
Northwestern UniversityCompletedHealthyUnited States
-
University of FloridaActive, not recruiting
-
Huashan HospitalUnknown
-
University of ManitobaRecruiting
-
University of PennsylvaniaCompletedAttention Deficit Disorder With Hyperactivity (ADHD)United States
-
Beth Israel Deaconess Medical CenterTerminated
-
Northwestern UniversityRecruiting